Gemcitabine With or Without Imatinib Mesylate in Treating Patients With Metastatic or Unresectable Kidney Cancer
Status:
Terminated
Trial end date:
2007-08-01
Target enrollment:
Participant gender:
Summary
RATIONALE: Drugs used in chemotherapy, such as gemcitabine, work in different ways to stop
the growth of tumor cells, either by killing the cells or by stopping them from dividing.
Imatinib mesylate may stop the growth of tumor cells by blocking some of the enzymes needed
for cell growth. Giving gemcitabine together with imatinib mesylate may kill more tumor
cells.
PURPOSE: This randomized phase II trial is studying gemcitabine and imatinib mesylate to see
how well they work compared with gemcitabine alone in treating patients with metastatic or
unresectable kidney cancer.
Phase:
Phase 2
Details
Lead Sponsor:
University of Medicine and Dentistry of New Jersey